115.31 0.00 (0.00%)
After hours: 4:37PM EST
|Bid||114.32 x 100|
|Ask||125.00 x 200|
|Day's Range||113.65 - 121.50|
|52 Week Range||92.65 - 143.37|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||154.00|
Yahoo Finance's Seana Smith, Andy Serwer, Ethan Wolff-Mann and Dion Rabouin discuss why now could be a good time to invest in marijuana stocks.
AbbVie (NYSE:ABBV) took center stage in yesterday’s biotechnology news arena with its potentially groundbreaking Alzheimer’s partnership but the company isn’t stopping there. As we head into the end of the week, news has hit press that a partnership between AbbVie and Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has just produced some trial data and both companies are […] The post Here Are Today’s Biotech Movers: Abbvie, Neurocrine and GW Pharmaceuticals appeared first on Market Exclusive.
GW Pharmaceuticals' CBDV drug strikes out in a phase 2a study. But there's a much more important catalyst ahead.
There is no doubt that the marijuana industry in the US has a lot of growth potential. The sale of medical and recreational weed is expected to reach $30 billion by 2021 from $6.50 billion this year. However, the opportunities to invest in the industry are pretty limited. There are many cannabis companies trading on […]
Shares of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) tumbled nearly 5% in after-hours trading Wednesday, after the drug maker announced negative results with GWP42006 in adult patients with focal seizures. The Phase 2a placebo-controlled study evaluated the efficacy and safety of GWP42006, which features cannabidivarin (CBDV) as the primary cannabinoid molecule, as add-on therapy in 162 adult patients with inadequately controlled focal seizures. In the trial’s preliminary top-line results, both active and placebo arms showed similar reductions in focal seizures of approximately 40 percent.
-Study did not meet its primary endpoint-. -Company remains committed to continued development of GWP42006 for autism spectrum disorders and will continue to explore the product’ s potential within the ...
" Wonder Women Of Weed " is a bi-monthly show and column featuring accomplished female leaders in the cannabis industry, brought from a collaborative effort that includes Benzinga, Industry Power ...
Analysts are bullish on these following companies: GW Pharmaceuticals, Geron, SmartFinancial. These companies are relatively strong financially, and have a great outlook in terms of profits and cash flow. IfRead More...
LONDON and CARLSBAD, Calif., Feb. 06, 2018-- GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid ...
NEW YORK, NY / ACCESSWIRE / February 6, 2018 / The markets recent selloff continued Monday as a result of rising interest rates. Both the Dow Jones and the S&P 500 fell sharply to close in negative territory ...
ADR (NASDAQ:GWPH) has garnered approval for the review of a new medication to treat seizure patients. The European Medicines Agency (EMA) has accepted the biopharmaceutical’s request to review the Market Authorization Application (MAA) of Epidiolex, or cannibidiol. The medication is used to treat patients who suffer from seizures linked to Lennox-Gastaut syndrome (LGS) and Dravet syndrome.
LONDON and CARLSBAD, Calif., Feb. 05, 2018-- GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercialising novel therapeutics from its proprietary cannabinoid ...
-Epidiolex ® NDA and MAA applications accepted for review–- NDA PDUFA goal date scheduled for June 27, 2018-- Conference call today at 4:30 p.m. EST-. LONDON and CARLSBAD, Calif., Feb. 05, 2018-- GW Pharmaceuticals ...
In this article we are going to present an alternative to weed stocks such as GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), Cara Therapeutics Inc (NASDAQ:CARA), Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP), and Insys Therapeutics Inc (NASDAQ:INSY). When it comes to investing in the marijuana industry many people think about stocks of companies that are either growing and/or selling […]
NEW YORK, NY / ACCESSWIRE / February 2, 2018 / Rising bond yields created mixed results on Wall Street Thursday. The S&P 500 Index declined 0.06 percent to close at 2,821.98, while the Nasdaq Composite ...
GW Pharma (GWPH) will report fiscal first-quarter results next week. Investors focus is expected to be on the Epidiolex commercialization plan.
Scotts Miracle-Gro missed Q1 views and said "slower-than-expected pace of regulatory changes in California" were harming its hydroponics business.
LONDON, Jan. 29, 2018-- GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, ...